

Notice under Section 708A(5)(e) of the Corporations Act

3 September 2025: Orthocell Limited ASX: OCC, “**Orthocell**” or “**the Company**”) is pleased to advise that it has today issued 1,500,000 fully paid ordinary shares (“**New Shares**”) following the exercise of 1,500,000 unlisted options, each with an exercise price of \$0.75 and expiring 2 December 2027.

The Company hereby gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (“**Act**”) of the issue of the New Shares. The Act restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or 708A of the Act. By the Company giving this notice (“**Notice**”), a sale of the New Shares will fall within the exemption in section 708A(5) of the Act and they will be able to be traded immediately.

For the purposes of section 708A(6) of the Act, the Company gives notice that:

- (a) the New Shares were issued without disclosure to investors under Part 6D.2 of the Act;
- (b) this Notice is being given under section 708A(5)(e) of the Act;
- (c) as at the date of this Notice the Company has complied with:
 - (i) the provisions of Chapter 2M of the Act, as they apply to the Company; and
 - (ii) sections 674 and 674A of the Act; and
- (d) as at the date of this Notice there is no information that is ‘excluded information’ within the meanings of sections 708(A)(7) and 708A(8) of the Act that is required to be set out in this notice.

Release authorised by the Board of Orthocell Limited.

For more information, please contact:

General enquiries

Paul Anderson

Orthocell Limited

CEO and MD

P: +61 8 9360 2888

E: paulanderson@orthocell.com.au

Media enquiries

Haley Chartres

HACK Director

P: +61 423 139 163

E: haley@hck.digital

Investor enquiries

Shaun Duffy

Vector Advisers

P: +61 404 094 384

E: sduffy@vectoradvisors.au

About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia



Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed 14 US distributors and recorded first sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand, Singapore, Thailand and Canada and is distributed by Device Technologies Group. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter **@OrthocellLtd** and LinkedIn www.linkedin.com/company/orthocell-ltd

